Common questions about OxyNEO (FAQ)
Q: What is the main difference between OxyNEO and regular oxycodone tablets?
According to official product information, OxyNEO is a Controlled-Release (CR) tablet, formulated to slowly release the medicine over an extended period, typically 12 hours. This design allows for continuous, around-the-clock pain management. Regular oxycodone is usually an Immediate-Release (IR) formulation, which is intended for 'as needed' use for pain that is not severe enough to require continuous treatment.
Q: Why did the manufacturer change the original formula to OxyNEO?
Regulatory documents indicate that the original formulation was withdrawn from the market for safety reasons related to the risk of abuse. The reformulated version (OxyNEO) possesses specific physical and chemical properties which led to the FDA recognizing its abuse-deterrent features, as these properties are expected to make certain methods of abuse, like injection or nasal use, more difficult.
Q: Does OxyNEO have a different safety warning than the original OxyContin?
Official labeling for the reformulated product (OxyNEO) was updated to specifically mention its abuse-deterrent properties, which differs from the original product. The U.S. FDA determined that the original formulation was withdrawn for safety reasons, which prevents generic copies of the original from being approved.
Q: Are there specific food items or beverages that should be avoided when taking OxyNEO?
Official product information emphasizes that alcohol use is advised against by regulatory documents because combining it with the medicine carries a risk of profound sedation and serious respiratory depression. Additionally, grapefruit juice should be avoided as it may increase the concentration of the medicine in the body, which could raise the risk of toxicity.
Q: How is OxyNEO generally described in official documents regarding the risk of physical dependence?
Physical dependence is described in regulatory documents as a known and expected outcome of continuous opioid treatment. Official guidance states that if a patient is physically dependent, they must undergo a gradual reduction (tapering) of the dose when stopping the medicine to help minimize the occurrence of withdrawal symptoms.
Q: What are the official recommendations regarding driving or operating heavy machinery while using OxyNEO?
Regulatory information indicates that caution is advised regarding driving or operating heavy machinery until the individual knows how the medicine affects them. This is because the medication can cause effects like dizziness and drowsiness, which may impair the mental and physical abilities needed for safe operation.
Q: How is the long-term use of OxyNEO addressed in regulatory information?
Studies and official information indicate that the effects of long-term use are not fully established in controlled clinical trials. Regulatory guidelines emphasize the importance of regular monitoring by the healthcare provider. The guidelines advise using the lowest effective dose for the shortest duration necessary, especially when prescribing for long periods.
Q: Does OxyNEO contain lactose or other inactive ingredients that people might be allergic to?
Yes, the official product description confirms that the tablet formulation contains lactose as an inactive ingredient. The tablets are also made with several other pharmaceutical excipients (inactive substances) used to create the controlled-release system.
Q: What is the 'abuse-deterrent' claim and how is it described in regulatory documents?
The abuse-deterrent claim refers to the formulation having physical and chemical properties that resist common methods of misuse, such as crushing, chewing, or dissolving. The design is recognized for properties that resist these actions and is expected to reduce abuse via the intranasal and injection routes.
Q: If a dose of OxyNEO is missed, what does the official labeling suggest doing?
According to the official patient counseling information, if a dose is missed, patients should skip the missed dose if it is nearly time for the next scheduled dose. The labeling indicates that the patient should not take two doses at one time to make up for the missed one.
Q: What are the official classifications of OxyNEO regarding its controlled substance status?
Oxycodone, the active ingredient in OxyNEO, is classified as a Schedule II controlled substance in the United States by the Drug Enforcement Administration (DEA). This regulatory classification signifies that the medicine has a high potential for abuse that may lead to severe physical or psychological dependence.
Q: What is the significance of the tablet's color or marking on OxyNEO pills?
Official descriptions state that the tablets are manufactured in different colors and include specific markings, such as imprint codes. The purpose of these differences is to allow for easy identification of the specific dosage strength of the oxycodone hydrochloride within the pill.
Q: Is constipation a universal side effect reported by all users of OxyNEO?
Official reports indicate that constipation is a Very Common adverse reaction, meaning it was reported in 1 out of every 10 or more patients during clinical studies. The classification 'Very Common' means it affects a significant portion of patients, but official documents do not describe any side effect as being universal.
